Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,451 | -11,372 | -4,614 | -21,126 | -15,812 |
| Depreciation Amortization | 1,435 | 935 | 450 | 1,758 | 1,281 |
| Accounts receivable | 11 | 11 | -106 | -775 | 1,343 |
| Accounts payable and accrued liabilities | 184 | -6 | -69 | 292 | 408 |
| Other Working Capital | -467 | 207 | 97 | 216 | 2,813 |
| Other Operating Activity | 2,649 | 1,921 | 404 | 4,295 | -785 |
| Operating Cash Flow | $-13,639 | $-8,304 | $-3,838 | $-15,340 | $-10,752 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,898 | N/A | N/A | 509 | N/A |
| PPE Investments | -102 | 98 | 112 | -189 | -368 |
| Net Acquisitions | N/A | N/A | N/A | 121 | 121 |
| Sale Of Investment | N/A | 1,160 | N/A | N/A | 509 |
| Investing Cash Flow | $-3,000 | $1,258 | $112 | $441 | $262 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 8 | N/A |
| Debt Repayment | -161 | -107 | -53 | -197 | -144 |
| Common Stock Issued | 42,449 | 7,089 | 3,333 | 10,958 | 5,409 |
| Financing Cash Flow | $42,288 | $6,983 | $3,279 | $10,770 | $5,266 |
| Beginning Cash Position | 3,377 | 3,377 | 3,377 | 7,507 | 7,507 |
| End Cash Position | 29,026 | 3,314 | 2,931 | 3,377 | 2,283 |
| Net Cash Flow | $25,649 | $-64 | $-446 | $-4,130 | $-5,225 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,639 | -8,304 | -3,838 | -15,340 | -10,752 |
| Capital Expenditure | -192 | -32 | -9 | -480 | -393 |
| Free Cash Flow | -13,831 | -8,336 | -3,847 | -15,820 | -11,145 |